|Chemical and physical data|
|Molar mass||410.49 g·mol−1|
|3D model (JSmol)|
QMPSB was first discovered by Lambeng and colleagues in 2007. It acts as a full agonist of the CB1 receptor and CB2 receptor with Ki values of 3 nM and 4 nM, respectively. Many related derivatives were subsequently produced, with the main focus of this work being to increase selectivity for the non-psychoactive CB2 receptor. This work led on from an earlier series of sulfamoyl benzamide derivatives for which a patent was filed in 2004.
|This cannabinoid related article is a stub. You can help Wikipedia by expanding it.|